| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30059022 | HIV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20008729 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20057196 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20056575 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20019982 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20019983 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS20019984 | HPV | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS44000358 | HTLV-1 | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS44005997 | HTLV-1 | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
| TVIS44030971 | HTLV-1 | ENSG00000121879.6 | protein_coding | PIK3CA | Yes | No | 5290 | P42336 Q4LE51 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PIK3CA |
|---|---|
| DrugBank ID | DB00171 |
| Drug Name | ATP |
| Target ID | BE0002379 |
| UniProt ID | P42336 |
| Regulation Type | |
| PubMed IDs | 18754654 |
| Citations | Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, Kugendradas A, Lensun L, Moore P, Olivero AG, Pang J, Patel S, Pergl-Wilson GH, Raynaud FI, Robson A, Saghir N, Salphati L, Sohal S, Ultsch MH, Valenti M, Wallweber HJ, Wan NC, Wiesmann C, Workman P, Zhyvoloup A, Zvelebil MJ, Shuttleworth SJ: The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . J Med Chem. 2008 Sep 25;51(18):5522-32. doi: 10.1021/jm800295d. |
| Groups | Investigational; Nutraceutical |
| Direct Classification | Purine ribonucleoside triphosphates |
| SMILES | NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O |
| Pathways | Glycerolipid Metabolism; Fatty Acid Metabolism; Pamidronate Action Pathway; Simvastatin Action Pathway; Citric Acid Cycle; Glutamate Metabolism; Argininosuccinic Aciduria; Gluconeogenesis; Betaine Metabolism; Butyrate Metabolism; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Rosuvastatin Action Pathway; Propanoate Metabolism; Pentose Phosphate Pathway; Pyruvate Metabolism; Inositol Metabolism; Zoledronate Action Pathway; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Pyrimidine Metabolism; Carbamoyl Phosphate Synthetase Deficiency; Ammonia Recycling; Histidine Metabolism; Pravastatin Action Pathway; Arginine and Proline Metabolism; Starch and Sucrose Metabolism; Purine Metabolism; Fluvastatin Action Pathway; Galactose Metabolism |
| PharmGKB | PA164743471 |
| ChEMBL | CHEMBL14249 |
